Plain-English translation of NCT05760287 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying advanced ultrasound techniques to better diagnose and understand cardiac amyloidosis — a serious condition where abnormal protein deposits damage the heart. The study will also track how patients respond to a new treatment called tafamidis, which is designed specifically for a type of amyloidosis caused by transthyretin protein problems. By collecting detailed ultrasound images over time, the research team hopes to find new ways to predict which patients are at highest risk for heart complications.
Amyloidosis can look similar to other heart conditions on standard tests, which sometimes leads to delayed or incorrect diagnosis. This study exists to develop better ultrasound methods that can reliably distinguish amyloidosis from other heart diseases, and to understand whether the new treatment actually reverses the heart damage it causes.
You likely qualify if…
You likely don't qualify if…
You will undergo heart ultrasounds at the Fondazione Policlinico Universitario Agostino Gemelli in Rome, including advanced imaging techniques that create detailed 2D and 3D pictures of your heart's function. If you are taking the new medication, researchers will use these ultrasounds to see whether your heart is improving over time. Your visits and medical records will be tracked as part of this observational study, meaning researchers are watching and recording what happens rather than assigning you to a specific treatment.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Italy